Opinion|Videos|February 14, 2025
Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
Panelists discuss how frailty assessment influences treatment decisions in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), particularly examining the IFM2017-03 study’s evaluation of a dexamethasone-sparing approach using daratumumab plus lenalidomide in frail patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does frailty impact treatment outcomes in transplant-ineligible NDMM?
- What are your thoughts on the IFM2017-03 study evaluating a dexamethasone-sparing regimen with daratumumab plus lenalidomide in frail patients with NDMM?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5